ArticleThe Lancet regional health. Europe2023
Trends in gabapentinoid prescribing in UK primary care using the Clinical Practice Research Datalink: an observational study.
Article in The Lancet regional health. Europe, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 44 citations in OpenAlex.
- Gabapentinoids and unexplained death in general practice: Case series and feasibility study arising from a critical incident.The European journal of general practice · 2026Article
- How the Reclassification of Gabapentinoids Reshaped Neuropathic Pain Treatment in Saudi Arabia: A Survey of Healthcare Professionals.Pain and therapy · 2026Article
- Opioid-specific risk of respiratory depression in non-cancer pain: a retrospective cohort study.BMC medicine · 2026Article
- Impact of secured prescription implementation on ambulatory pregabalin use in France: A regional assessment in the French Nouvelle-Aquitaine.British journal of clinical pharmacology · 2026Article
- Exploring medication safety in prisons: a scoping review.BMJ open · 2026Article
- Prescription Trends and Clinical Decision-Making in Neuropathic Pain Pharmacological Treatment: Results From a Cross-Sectional Survey by the Spanish Pain Society.European journal of pain (London, England) · 2026Article
- A comprehensive analysis of jurisdiction-specific laws related to scheduling or required prescription drug monitoring of gabapentin in the United States, 2016-2024.The International journal on drug policy · 2026Article
- Thyroid disease-attributed mortality burden and temporal trends among U.S. adults aged ≥65 years, 1999-2023: a nationwide analysis based on the CDC WONDER database.Frontiers in public health · 2026Article
- Trends in analgesia prescribing in primary care in Ireland and England between 2014 and 2022: A repeated cross-sectional study.British journal of clinical pharmacology · 2025Article
- A cross-sectional study of prescribing of antiseizure medication for the treatment of pain in Australia.International journal of clinical pharmacy · 2025Article
- Pain and Sedative Medication Use Among Individuals With Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study.Alimentary pharmacology & therapeutics · 2025Article
- High-dose use of pregabalin and gabapentin in France: a retrospective, population-based cohort study.The Lancet regional health. Europe · 2025Article
- Trends in gabapentinoid prescribing: A nationwide Danish drug utilization study.British journal of clinical pharmacology · 2025Article
- How Should Non-Prescribed Use of Gabapentinoids be Reduced in Psychiatric Practice?Human psychopharmacology · 2025Article
- Article
- Use of gabapentinoid treatment and the risk of self-harm: population based self-controlled case series study.BMJ (Clinical research ed.) · 2025Article
- Prescribing practices for proton pump inhibitors among primary care physicians in England: an evaluation.BJGP open · 2025Article
- Incident gabapentin prescribing associated with opioid and benzodiazepine/Z-drug prescribing - a population-based longitudinal study in primary care.Frontiers in pharmacology · 2025Article
- Analysis of User-Generated Posts on Social Media of Adjuvant Analgesics: A Machine Learning Study.International journal of medical sciences · 2025Article
- Gabapentinoids and Risk of Hip Fracture.JAMA network open · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The UK government reclassified gabapentin and pregabalin as 'controlled drugs' from April 2019. This study aimed to describe the trends in gabapentinoid prescribing before and immediately after reclassification, in the UK Clinical Practice Research Datalink, an electronic primary care health record broadly representative of the UK. Methods: Separately for gabapentin and pregabalin, we calculated annual incident and prevalent prescribing rates from year of UK approval (April 1997 and 2004 respectively) to September 2019, and monthly incident and prevalent prescribing rates (October 2017-September 2019). Significant changes in temporal trends were determined using joinpoint regression. We also described potential prescribing indications, prior pain-related prescribing, and co-prescribing with potentially interacting medicines. Findings: Incident gabapentin prescribing increased annually, peaking in 2016-17, at 625/100,000 patient years before falling steadily to 2019. Incident pregabalin prescribing peaked at 329/100,000 patient years in 2017-18 and did not fall significantly until 2019. Prevalent gabapentin and pregabalin prescribing increased annually to 2017-18 and 2018-19 respectively, before plateauing. Gabapentinoids were commonly co-prescribed with opioids (60%), antidepressants (52%), benzodiazepines (19%), and Z-drugs (10%). Interpretation: Following a dramatic rise, incident gabapentinoid prescribing has started to fall but the specific impact of reclassification on prescribing rates remains unclear. Limited change in prevalent gabapentinoid prescribing during the 6 months following their reclassification as controlled drugs suggests little immediate impact on continued gabapentinoid prescribing for existing users. Funding: National Institute for Health and Care Research (NIHR) Research for Patient Benefit Programme. NIHR Applied Research Collaboration West Midlands. NIHR School for Primary Care Research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.